The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05763576




Registration number
Help: Registration number
NCT05763576
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
28/02/2023
Date registered
Help: Date registered
10/03/2023
Date last updated
Help: Date last updated
22/01/2026

Titles & IDs
Public title
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
Scientific title
A Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
Additional trial identifiers [1] 0 0
EU Trial Number
Additional trial identifiers [2] 0 0
BP44118
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Chronic Hepatitis B 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - RO7565020
Other interventions - Placebo
Treatment: Drugs - Nucleos(t)ide analogue (NUC) treatment

Experimental: RO7565020 -

Placebo comparator: Placebo -


Treatment: Drugs: RO7565020
RO7565020 will be administered by subcutaneous injection or intravenous infusion.

Other interventions: Placebo
Matching placebo will be administered by subcutaneous injection or intravenous infusion.

Treatment: Drugs: Nucleos(t)ide analogue (NUC) treatment
NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.

Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Part 1a: Number of Healthy Volunteers With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [1] 0 0
Up to approximately 40 weeks
Primary outcome [2] 0 0
Part 2a: Number of CHB Participants With AEs and SAEs
Timepoint [2] 0 0
Up to approximately 32 weeks
Primary outcome [3] 0 0
Part 1a: Number of Healthy Volunteers With Adverse Events of Special Interest (AESI)
Timepoint [3] 0 0
Up to approximately 40 weeks
Primary outcome [4] 0 0
Part 2a: Number of CHB Participants With AESI
Timepoint [4] 0 0
Up to approximately 32 weeks
Secondary outcome [1] 0 0
Part 1a (SC Cohorts) and Part 2a: Time to Maximum Concentration (Tmax) of RO7565020
Timepoint [1] 0 0
Part 1a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197, and 253. Part 2a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Secondary outcome [2] 0 0
Part 1a (IV Cohorts): Tmax of RO7565020
Timepoint [2] 0 0
Predose, 0.08, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197, and 253
Secondary outcome [3] 0 0
Parts 1a and 2a: Maximum Serum Concentration (Cmax) of RO7565020
Timepoint [3] 0 0
Both Part 1a & 2a Cohorts: Predose, 1, 4, 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 29, 57, 85, & 141. Additionally, Part 1a: Days 21, 197, & 253; Part 2a: Days 22, 113, & 169; IV Cohorts: 0.08 hours after start of infusion, Days 21, 197, & 253
Secondary outcome [4] 0 0
Parts 1a and 2a: Area Under the Time-concentration Curve From Time 0 to Time of Last Sampling Point or Last Quantifiable Sample, Whichever Comes First (AUC0-last) of RO7565020
Timepoint [4] 0 0
Both Part 1a & 2a Cohorts: Predose, 1, 4, 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 29, 57, 85, & 141. Additionally, Part 1a: Days 21, 197, & 253; Part 2a: Days 22, 113, & 169; IV Cohorts: 0.08 hours after start of infusion, Days 21, 197, & 253
Secondary outcome [5] 0 0
Parts 1a and 2a: Area Under the Time-concentration Curve From Time 0 to Infinity (AUC0-inf) of RO7565020
Timepoint [5] 0 0
Both Part 1a & 2a Cohorts: Predose, 1, 4, 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 29, 57, 85, & 141. Additionally, Part 1a: Days 21, 197, & 253; Part 2a: Days 22, 113, & 169; IV Cohorts: 0.08 hours after start of infusion, Days 21, 197, & 253
Secondary outcome [6] 0 0
Parts 1a and 2a: Terminal Half-life (t1/2) of RO7565020
Timepoint [6] 0 0
Both Part 1a & 2a Cohorts: Predose, 1, 4, 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 29, 57, 85, & 141. Additionally, Part 1a: Days 21, 197, & 253; Part 2a: Days 22, 113, & 169; IV Cohorts: 0.08 hours after start of infusion, Days 21, 197, & 253
Secondary outcome [7] 0 0
Part 1a (IV Cohorts): Volume of Distribution (Vss) of RO7565020
Timepoint [7] 0 0
Predose, 0.08, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197 and 253
Secondary outcome [8] 0 0
Part 1a (IV Cohorts): Clearance (CL) of RO7565020
Timepoint [8] 0 0
Predose, 0.08, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197 and 253
Secondary outcome [9] 0 0
Part 1a (SC Cohorts) and Part 2a: Apparent Clearance (CL/F) of RO7565020
Timepoint [9] 0 0
Part 1a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197, and 253. Part 2a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Secondary outcome [10] 0 0
Part 1a (SC Cohorts) and Part 2a: Apparent Volume of Distribution (Vz/F) at Terminal Phase of RO7565020
Timepoint [10] 0 0
Part 1a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197, and 253. Part 2a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Secondary outcome [11] 0 0
Part 2a: Change From Baseline in Serum Quantitative Hepatitis B Surface Antigen (HBsAg)
Timepoint [11] 0 0
Baseline, 4- and 8-hours post-dose on Day 1; subsequently on Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Secondary outcome [12] 0 0
Part 2a: Maximum Reduction From Baseline in Serum HBsAg
Timepoint [12] 0 0
Up to Day 169
Secondary outcome [13] 0 0
Part 2a: Percentage of Participants With HBsAg Loss
Timepoint [13] 0 0
Up to Day 169
Secondary outcome [14] 0 0
Part 2a: Percentage of Participants With HBsAg Seroconversion
Timepoint [14] 0 0
Up to Day 169
Secondary outcome [15] 0 0
Part 2a: Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss Among HBeAg-positive Participants at Baseline
Timepoint [15] 0 0
At Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Secondary outcome [16] 0 0
Part 2a: Percentage of Participants With HBeAg Seroconversion Among HBeAg-positive Participants at Baseline
Timepoint [16] 0 0
Up to Day 169
Secondary outcome [17] 0 0
Number of Participants With Anti-Drug Antibodies (ADAs) to RO7565020
Timepoint [17] 0 0
Part 1a: Baseline and post-baseline (up to approximately 40 weeks); Part 2a: Baseline and post-baseline (up to approximately 32 weeks)

Eligibility
Key inclusion criteria
Healthy volunteers:

* Healthy participants
* Body mass index (BMI) between 18 and 32 kg/m^2

CHB participants:

* CHB infection (HBsAg-positive for >/= 6 months)
* On NUC (ETV, TAF, or TDF) monotherapy for >/= 12 months
* Liver biopsy, FibroScan, or equivalent test within the past 6 months demonstrating liver disease consistent with chronic HBV infection without evidence of bridging fibrosis or cirrhosis
* BMI between 18 and 32 kg/m^2
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Healthy volunteers:

* History of any clinically significant disease
* Concomitant disease that could interfere with treatment or conduct of study
* Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)

CHB participants:

* Evidence of liver cirrhosis or decompensated liver disease
* History or suspicion of hepatocellular carcinoma (HCC)
* History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease
* History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
Hong Kong
State/province [2] 0 0
Hong Kong
Country [3] 0 0
Hong Kong
State/province [3] 0 0
Shatin, New Territories
Country [4] 0 0
New Zealand
State/province [4] 0 0
Auckland
Country [5] 0 0
South Korea
State/province [5] 0 0
Chuncheon
Country [6] 0 0
Spain
State/province [6] 0 0
Pontevedra
Country [7] 0 0
Taiwan
State/province [7] 0 0
Taoyuan
Country [8] 0 0
Thailand
State/province [8] 0 0
Bangkok
Country [9] 0 0
Thailand
State/province [9] 0 0
Chiang Mai

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Reference Study ID Number: BP44118 https://forpatients.roche.com/
Address 0 0
Country 0 0
Phone 0 0
888-662-6728 (U.S. Only)
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

Results publications and other study-related documents

No documents have been uploaded by study researchers.